A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients

Trial Profile

A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs ARO-HBV (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 08 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 07 Mar 2018 Planned initiation date changed from 5 Mar 2018 to 27 Mar 2018.
    • 15 Feb 2018 According to an Arrowhead Pharmaceuticals media release, the company anticipates that dosing will begin around the end of March.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top